Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00090077
First received: August 24, 2004
Last updated: February 24, 2006
Last verified: February 2006

August 24, 2004
February 24, 2006
April 2004
Not Provided
Safety & tolerability parameters Change from baseline in plasma HIV-1 RNA Change from baseline in CD4+ cell count Plasma GW678248X pharmacokinetic parameters Days 1 & 7
Not Provided
Complete list of historical versions of study NCT00090077 on ClinicalTrials.gov Archive Site
Plasma GW695634X pharmacokinetic parameters on Day 1 and Day 7 Exploratory relationship of pharmacokinetic parameters to changes in virology, immunology and/or safety assessments
Not Provided
Not Provided
Not Provided
 
Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults
A Phase I, Multicenter, Randomized, Parallel, Double-Blinded Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Four Oral Dosage Regimens of GW695634G Monotherapy Versus Placebo Over 10 Days in ART-Naive HIV-1 Infected Adults.
To investigate safety, tolerability and antiviral activity in Non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced HIV-1 infected patients
Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
HIV Infections
Drug: GW695634
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
Not Provided
Not Provided

Inclusion criteria:

  • CD4 cell count greater than or equal to 200 cells/mm3.
  • HIV-1 RNA >2000 copies/mL.
  • Must have history of NNRTI treatment with subsequent failure and documented evidence of an NNRTI-associated mutation or a phenotype displaying reduced activity to efavirenz, nevirapine or delavirdine.
  • Normal resting 12-lead electrocardiogram.

Exclusion criteria:

  • Any history of seizure, CNS toxoplasmosis infection, or any CNS (central nervous system) lesion.
  • Chronic diarrhea (>3 loose stools/day).
  • An active CDC Category C disease (1993), except cutaneous Kaposi's Sarcoma (KS) not requiring systemic therapy during the trial.
  • Less than 4 weeks since stopping anti-retroviral therapy (ART) therapy prior to Day 1.
  • Any acute laboratory abnormality.
  • Positive for HCV antibody or HepBsAG.
  • Active infections requiring therapy in the previous 4 weeks.
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00090077
NN210005
Not Provided
Not Provided
Not Provided
Not Provided
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trial, MD GlaxoSmithKline
GlaxoSmithKline
February 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP